Clear benefit with ace inhibitors: study

The study of 35 trials in 56,000 patients with diabetes showed that ACE inhibitors reduced all-cause mortality by 13%, CV deaths by 17% and major CV events by 14% compared to active control or placebo.

In contrast, ARBs did not affect all-cause mortality, CV death rates or major CV events, with the exception of heart failure, which was reduced by 30% compared to active controls or placebo.

The beneficial effects of ACE inhibitors on all-cause mortality and CV death were not affected by baseline blood pressure or the type of ACE inhibitor